Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
Trial Parameters
Brief Summary
This study is a prospective, multicenter, single arm Phase II exploratory study. It is expected to include 24 first-line patients with small cell lung cancer who have progressed after 6 months of treatment with platinum containing regimens, and receive treatment with irinotecan liposomes combined with cisplatin or carboplatin regimens.
Eligibility Criteria
Inclusion Criteria: * The patient fully understands this study, voluntarily participates and signs an informed consent form (ICF). * Age ≥ 18 years old; * Patients with extensive stage small cell lung cancer diagnosed by pathology or histology; * According to RECIST 1.1 standard, patients have at least one measurable target lesion; For lesions that have undergone radiation therapy in the past, they can only be included as measurable lesions if there is clear disease progression after radiation therapy; * Progression confirmed by imaging examination after 6 months of first-line radiotherapy and chemotherapy containing platinum drugs or platinum regimen radiotherapy and chemotherapy ± immunotherapy; * Eastern Cancer Collaborative Group (ECOG) physical fitness score: 0-2 points; * Estimated survival time ≥ 3 months; * Absolute neutrophil count (ANC) ≥ 1.5 x 10 \^ 9/L, platelet count ≥ 90 x 10 \^ 9/L, and hemoglobin count ≥ 90 g/L (no blood transfusion, blood products, use of granulocyte c